Webcast Sessions

Educational Sessions

SATURDAY, APRIL 14
8:00 a.m. to 10:00 a.m.

How to Design and Interpret Large-Scale Sequence Analyses of Human Cancer

Chairperson: Victor E. Velculescu, Johns Hopkins Oncology Center, Baltimore, MD

Mutational analyses of human cancer, Victor E. Velculescu, Johns Hopkins Oncology Center, Baltimore, MD
Application of new sequencing technologies to exon-based resequencing in human cancers, P. Andrew Futreal, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Elegance, missense, and nonsense in tumor mutations, Scott E. Kern, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Genome profiling as a guide to sequencing in breast cancer, Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA

Manipulating the Immune System in Cancer Immunotherapy

Chairperson: James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY

Cancer immunoediting from bench to bedside, Robert D. Schreiber, Washington University, St. Louis, MO
Improving the wiring of cancer vaccines, Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA
Engineering anti-tumor T cells, Phillip D. Greenberg, University of Washington, Seattle, WA
Blocking inhibitory checkpoint, James P. Allison, Memorial Sloan-Kettering Cancer Center, New York, NY

Modeling Chemoprevention in Mice: The Next Generation

Chairperson: Cory Abate-Shen, UMDNJ-R.W. Johnson Medical School, Piscataway, NJ

Issues in cancer prevention research, William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Modeling chemoprevention for prostate cancer in mutant mice, Cory Abate-Shen, UMDNJ-R.W. Johnson Medical School, Piscataway, NJ
Using mouse models to develop agents for the prevention of breast cancer, Powel H. Brown, Baylor College of Medicine, Houston, TX
Experimental compounds impacting translation of chemoprevention studies from mice to humans, David W. Threadgill, University of North Carolina, Chapel Hill, NC

Novel Approaches to Drug Delivery in Cancer

Chairperson: Mark E. Davis, California Institute of Technology, Pasadena, CA

Fundamental issues in nanoparticle therapeutics for cancer, Mark E. Davis, California Institute of Technology, Pasadena, CA
Nanotechnology: A novel approach to drug delivery in cancer therapeutics, Dong M. Shin, Emory University Winship Cancer Institute, Atlanta, GA
Potent immunoconjugates for cancer therapy, Peter D. Senter, Seattle Genetics, Bothell, WA
Targeting strategies: Engineered antibodies and proteins, Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA

Oxidative Stress and Senescence

Chairperson: Amato J. Giaccia, Stanford University School of Medicine, Stanford, CA

Ras-dependent mechanisms of tumorigenesis and senescence, Karen Cichowski, Brigham and Women’s Hospital, Boston, MA
Dissecting the role of the p53 tumor suppressor gene in senescence, Laura D. Attardi, Stanford University School of Medicine, Stanford, CA
Regulation of heterochromatin formation in senescent cells, Peter D. Adams, Fox Chase Cancer Center, Philadelphia, PA
Telomerase, stem cells, and senescence, Steven E. Artandi, Stanford, CA

The Polygenic Basis of Phenotypic Variation and Disease: Lessons from Humans and Model Organisms

Chairperson: Bruce A. J. Ponder, Hutchison/MRC Research Center, Cambridge, United Kingdom

The genetic architecture of complex traits: Lessons from drosophila, Trudy F. Mackay, North Carolina State University, Raleigh, NC
Genetic dissection of complex traits using outbred mice, Jonathan Flint, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
Lessons about polygenic traits from yeast, Lars Steinmetz, European Molecular Biology Laboratory, Heidelberg, Germany
Integrating genetic, molecular profiling, and clinical data to reconstruct gene networks driving disease: An integrative genomics approach to systems biology, Eric E. Schadt, Rosetta Inpharmatics, Seattle, WA

Therapeutic Cancer Targets in the Wnt Pathway

Chairperson: Hans Clevers, Hubrecht Laboratory, Utrecht, The Netherlands

Wnt target genes as therapeutic targets in colon cancer, Hans Clevers, Hubrecht Laboratory, Utrecht, The Netherlands
Going against the grain: Promoting Wnt signaling to conquer cancer, John D. Shaughnessy, Jr., University of Arkansas for Medical Sciences, Little Rock, AR
R-spondins are secreted Wnt agonists with potential use in the damaged intestinal tract, Kyung-Ah Kim, Nuvelo, Inc., San Carlos, CA
Identifying and inhibiting cancers driven by Wnt, Paul G. Polakis, Genentech, Inc., South San Francisco, CA

Validating Therapeutic Targets: In Vivo Models and Clinical Responses

Chairperson: Lynda Chin, Dana-Farber Cancer Institute, Boston, MA

Validating oncogenes as therapeutic targets in conditional transgenic models, Dean W. Felsher, Stanford University School of Medicine, Stanford, CA
Probing cancer phenotypes using mouse models and RNAi, Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Response prediction in engineered models: Using natural variation in preclinical tumor populations to assess the genetic context of drug response, Murray O. Robinson, AVEO Pharmaceuticals, Inc., Cambridge, MA
Acquired drug resistance and kinase addiction: Validating EGFR as a therapeutic target, Jeffrey Settleman, Massachusetts General Hospital Cancer Center, Charlestown, MA

SATURDAY, APRIL 14
10:15 a.m. to 12:15 p.m.

Cancer Biomarkers: Predictors of Prognosis and Response

Chairperson: William S. Dalton, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Architecture for future of personalized medicine, Timothy J. Yeatman, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Defining and understanding the role of prognostic genes in lung cancer, David G. Beer, University of Michigan, Ann Arbor, MI
Microarray-based molecular predictors of prognosis and therapy response in bladder cancer, Torben F. Orntoft, University of Aarhus, Aarhus, Denmark
Partners preparing for the future, Stephen H. Friend, Merck and Co., Inc., North Wales, PA

Controlling Epigenetic Programs: Consequences for Stem Cells and Carcinogenesis

Chairperson: Thea D. Tlsty, UCSF School of Medicine, San Francisco, CA

Title to be announced, Laurie Jackson-Grusby, Harvard Medical School, Boston, MA
Title to be announced, Robert Blelloch, University of California, San Francisco, CA
Additional speakers to be announced

Facilitating Collaborations Between Clinicians and Basic Researchers in the Era of Translational Research

Chairperson: Paul Workman, UK Center for Cancer Therapeutics, Sutton, United Kingdom

Speakers and titles to be announced

Inflammation and Cancer

Chairperson: Lisa M. Coussens, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA

Introduction and association of immune cells and cancers, Lisa M. Coussens, UCSF Comprehensive Cancer Center and Cancer Research Institute, San Francisco, CA
Crosstalk between humoral and innate immunity promotes epithelial cancer development, Karen E. de Visser, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Tumor immunity: A balancing act between immune suppression and immune enhancement, Suzanne Ostrand-Rosenberg, University of Maryland, Baltimore, MD
TNF-a: A cytokine that links inflammation and cancer, Frances R. Balkwill, Barts and The London Queen Mary’s School, London, United Kingdom

Systems Biology as an Integrative Approach to Cancer

Chairperson: Arul M. Chinnaiyan, University of Michigan Medical School, Ann Arbor, MI

Systems biology and systems medicine, Leroy E. Hood, The Institute for Systems Biology, Seattle, WA
Applying the concepts of systems biology toward in vivo and in vitro diagnostics of cancer via technology development, James R. Heath, California Institute of Technology, Pasadena, CA
Systems approaches to predictive markers, Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
Genomic strategies towards pathway analysis in cancer, Joseph R. Nevins, Duke University Institute for Genome Science and Policy, Durham, NC

Targeted Cancer Therapy: Mono-specific versus Multi-targeted Strategies

Chairperson: Axel Ullrich, Max-Planck Institute of Biochemistry, Martinsried, Germany

Title to be announced, Alexander Levitzki, Hebrew University, Jerusalem, Israel
Additional speakers and titles to be announced

Targeted Delivery of siRNA and Small Molecule Inhibitors

Chairperson: Jackson B. Gibbs, AstraZeneca, Waltham, MA

Multifunctional nanoparticles for cancer therapy and imaging, Omid C. Farokhzad, Brigham and Women’s Hospital, Boston, MA
Aptamers for cancer diagnostics, Andrew Ellington, The University of Texas, Austin, TX
Targeting siRNAs to cancer cells via aptamers, Bruce A. Sullenger, Duke University Medical School, Durham, NC
Polymer anticancer drug conjugates: Use as single agents and as combination therapy, María Jesús Vicent, Centro de Investigación Príncipe Felipe, Valencia, Spain

The Ras Pathway: From Cancer Biology to Translational Opportunities

Chairperson: Dafna Bar-Sagi, New York University School of Medicine, New York, NY

Turning MAP kinase pathway inhibitors into the real deal: What’s left to do?, Judith S. Sebolt-Leopold, Pfizer, Inc., Ann Arbor, MI
Targeting Ras/RalGDS/Ral and Ras/PI3K/Akt with GGTIs and Akt inhibitors, Said M. Sebti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Translating pathways to pancreatic cancer, Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA
Ras signaling: Found in translation, Dafna Bar-Sagi, New York University School of Medicine, New York, NY

SATURDAY, APRIL 14
1:00 p.m. to 3:00 p.m.

Metabolism and Cancer

Chairperson: Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, United Kingdom

Reactivating prolyl hydroxylases to suppress tumors with impaired oxidative phosphorylation, Eyal Gottlieb, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
The LKB1 kinase: Tumor suppressor and key regulator of glucose metabolism, Reuben J. Shaw, The Salk Institute for Biological Studies, La Jolla, CA
Role of MYC and HIF in the Warburg effect and tumorigenesis, Chi Van Dang, Johns Hopkins University School of Medicine, Baltimore, MD
Glycolysis and mitochondria: Selective master switches of tumor cells, Valeria R. Fantin, Merck and Co., Inc., Boston, MA

Models and Assays for Drug Discovery and Development

Chairperson: J. Martin Brown, Stanford University School of Medicine, Stanford, CA

Target identification using high throughput siRNA screening, René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands
In vitro assays that predict for in vivo activity, J. Martin Brown, Stanford University School of Medicine, Stanford, CA
Rational use of human tumor xenografts for drug development, Peter J. Houghton, St. Jude Children’s Research Hospital, Memphis, TN
Use of genetically engineered models in preclinical testing, Kevin M. Shannon, University of California, San Francisco, CA

Non-invasive Imaging (MRI, PET and Optical Imaging) in Detecting Disease, Evaluating Responses to Therapy, and Guiding Subsequent Treatment

Chairperson: Kevin M. Brindle, University of Cambridge, Cambridge, United Kingdom

Title to be announced, Sanjiv Sam Gambhir, Stanford University, Stanford, CA
Title to be announced, Alnawaz Rehemtulla, University of Michigan, Ann Arbor, MI
Title to be announced, Jeffrey L. Evelhoch, Amgen, Inc., Thousand Oaks, CA
Detecting early tumor responses to therapy using magnetic resonance imaging and spectroscopy, Kevin M. Brindle, University of Cambridge, Cambridge, United Kingdom

Plasma Biomarkers: Applications in Oncology

Chairperson: Gary J. Kelloff, National Cancer Institute, Rockville, MD

New markers for early detection of prostate cancer: Autoantibodies and auto-antigens in serum of prostate cancer patients, Arul M. Chinnaiyan, University of Michigan Medical School, Ann Arbor, MI
Kinase activation in circulating cells as biomarkers for diagnosis and therapeutic monitoring, Stephen J. Kron, University of Chicago, Chicago, IL
Origin and prospective utility of tumor-specific serum peptidome patterns, Josep Villanueva, Memorial Sloan-Kettering Cancer Center, New York, NY
Status technology development and progress in the development of blood-based biomarkers, David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
Title to be announced, Gary J. Kelloff, National Cancer Institute, Rockville, MD

Rho GTPases: Cytoskeleton and Cancer

Chairperson: Christopher J. Marshall, Institute of Cancer Research, London, United Kingdom

Rho GTPases in cell biology, Alan Hall, Memorial Sloan-Kettering Cancer Center, New York, NY
Signaling from the EGF-receptor to chemotaxis in metastatic carcinoma cells, John S. Condeelis, Albert Einstein College of Medicine, Bronx, NY
All “Rhos” lead to cancer progression, Kenneth L. van Golen, University of Delaware, Newark, DE
Rho family GTPase signaling in tumor cell movement and angiogenesis, Christopher J. Marshall, Institute of Cancer Research, London, United Kingdom

The Epigenetic Road from Stem Cells to Cancer

Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

The chromatin of stem cells: Links to aberrant gene silencing in cancer?, Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD
Epigenetic profiling of stem cells, Bradley E. Bernstein, Massachusetts General Hospital, Charlestown, MA
Identification of chromatin modifying enzymes in cancer, Kristian Helin, University of Copenhagen, Copenhagen, Denmark
Epigenetic regulation of stem cell phenotype and differentiation, Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA

The Next Wave: What are the Most Promising Targets for Antibody-based Drugs?

Chairperson: James DeCaprio, Dana-Farber Cancer Institute, Boston, MA

Speakers and titles to be announced

Translational Cancer Research in the Future: The Report of the National Cancer Institute Translational Research Working Group (TRWG)

Co-Chairpersons: William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, and Lynn M. Matrisian, Vanderbilt University School of Medicine, Nashville, TN

The report of the translational research working group, Ernest T. Hawk, National Institutes of Health, Rockville, MD
Translational research opportunities in cancer molecular biomarkers, Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA
Translational research opportunities in new cancer drugs, Sara A. Courtneidge, The Burnham Institute, La Jolla, CA
Translational research opportunities in cancer imaging, Gary S. Dorfman, National Cancer Institute, Rockville, MD

SATURDAY, APRIL 14
3:15 p.m. to 5:15 p.m.

Alternative Approaches to Small Molecule Drug Discovery (protein-protein interactions)

Co-Chairpersons: William R. Sellers, Novartis Institute of Biomedical Research, Cambridge, MA, and Carlos Garcia-Echeverria, Novartis Pharma, Inc., Basel, Switzerland

Taming a protein-protein interaction: The design and synthesis of IAP antagonists, Christopher S. Straub, Novartis Institutes for Biomedical Research, Cambridge, MA
A “credit-card” small molecule library approach to disrupting protein-protein interactions: Case studies from cancer to Alzheimer’s disease, Kim Janda, Scripps Research Institute, La Jolla, CA
Potent, specific, non-peptidic, small-molecule inhibitors of the human MDM2-p53 interaction as a new class of anticancer therapy, Shaomeng Wang, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
Approaches for targeting protein-protein interactions, Stephen W. Fesik, Abbott Laboratories, Abbott Park, IL

MicroRNAs

Chairperson: Carlo M. Croce, Ohio State University, Columbus, OH

Title to be announced, Curtis C. Harris, National Cancer Institute, Bethesda, MD
Title to be announced, George Coukas, University of Pennsylvania Medical Center, Philadelphia, PA

Preneoplasia: Predicting the Behavior of the Early Lesion

Chairperson: Rebecca Fitzgerald, Hutchison/MRC Research Center, Cambridge, United Kingdom

Risk stratification and screening for colon cancer without colonoscopy, Vadim Backman, Northwestern University, Evanston, IL
Pancreatic cancer medicine in mice, David A. Tuveson, Cambridge Research Institute, Cambridge, United Kingdom
Is early detection of cancer with serum biomarkers or proteomic profiling feasible?, Eleftherios P. Diamandis, Mount Sinai Hospital, Toronto, ON, Canada
Molecular tools for predicting the behavior of Barrett’s esophagus, Rebecca Fitzgerald, Hutchison/MRC Research Center, Cambridge, United Kingdom

Targeting Protein Translation in Cancer

Chairperson: Nahum Sonenberg, McGill University, Montreal, QC, Canada

Small-molecule of protein–protein interactions in translation initiation as potential antitumor agents, Gerhard Wagner, Harvard Medical School, Boston, MA
Exploring translation initiation as a chemotherapeutic target, Jerry Pelletier, McGill University, Montreal, QC, Canada
Targeting the protein translation factor eIF-4E for cancer therapy, Jeremy R. Graff, Eli Lilly and Company, Indianapolis, IN
Targeting protein translation in human tumors: P-4EBP1 as a key clinical-molecular factor, Santiago Ramon y Cajal, Vall d’ Hebron Hospital, Barcelona, Spain

Targeting Ras Pathways in Cancer

Chairperson: Mariano Barbacid, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

Genetic dissection of Ras function in vivo, Mariano Barbacid, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
Ras signaling through the PI3 kinase pathway, Speaker to be announced
Ras signaling through the Raf pathway, Richard M. Marais, The Institute of Cancer Research, London, United Kingdom
Selective inhibitors to target Ras signaling pathways, Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Toll Receptors, Immunity, and Cancer

Chairperson: Louis M. Weiner, Fox Chase Cancer Center, Philadelphia, PA

Title to be announced, Bruce Beutler, The Scripps Research Institute, La Jolla, CA
Title to be announced, Randolph J. Noelle, Dartmouth College, Hanover, NH
Control of regulatory T cells and cancer immunity by toll-like receptors, Rongfu Wang, Baylor College of Medicine, Houston, TX
Inducing antitumor immunity by targeting toll-like receptor 9 with CpG oligodeoxynucleotides, Arthur M. Krieg, Coley Pharmaceutical Group, Wellesley, MA